» Articles » PMID: 16360067

Mode of Death in Advanced Heart Failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) Trial

Overview
Date 2005 Dec 20
PMID 16360067
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The aim of this study was to evaluate the mode of death in patients with advanced chronic heart failure (HF) and intraventricular conduction delay treated with optimal pharmacologic therapy (OPT) alone or OPT with biventricular pacing to provide cardiac resynchronization therapy (CRT) or CRT + an implantable defibrillator (CRT-D).

Background: Limited data are available on mode of death in advanced HF. No data have existed on mode of death in these patients who also have an intraventricular conduction delay and are treated with CRT or CRT-D.

Methods: Using prespecified definitions and source materials, seven cardiologists assessed mode of death among the 313 deaths that occurred in the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial.

Results: A primary cardiac cause was present in 78% of deaths. Pump failure (44.4%) was the most common mode of death followed by sudden cardiac death (SCD) (26.5%). Compared with OPT, CRT-D significantly reduced the number of cardiac deaths (38%, p = 0.006), whereas CRT alone was associated with a non-significant 14.5% reduction (p = 0.33). Both CRT and CRT-D tended to reduce pump failure deaths (29%, p = 0.11 and 27%, p = 0.14, respectively). The CRT-D significantly reduced SCD (56%, p = 0.02), but CRT alone did not.

Conclusions: Pump failure deaths are the predominant mode of death in patients with advanced HF and are modestly reduced by both CRT and CRT-D. Only CRT-D reduced SCD and thus produced a favorable effect on cardiac mortality.

Citing Articles

Pacemaker Versus Defibrillator Therapy in Patients Eligible for Cardiac Resynchronisation Therapy: Evidence from the German Device Registry.

Lange P, Frommeyer G, Kleemann T, Brachmann J, Lugenbiel P, Reif S J Clin Med. 2025; 14(4).

PMID: 40004671 PMC: 11856535. DOI: 10.3390/jcm14041137.


Clinical Impact of Digitalis Therapy in a Large Multicenter Cohort of CRT-Recipients.

Erath J, Vigh N, Muk B, Israel C, Keck S, Pilecky D J Cardiovasc Dev Dis. 2024; 11(6).

PMID: 38921673 PMC: 11203494. DOI: 10.3390/jcdd11060173.


Association between admission serum potassium level and 30-day all-cause mortality in patients with emergency admission for heart failure: A secondary analysis based on a Norwegian retrospective cohort.

Zhang K, Yang P, Cheng M, Yin D, Li M, Xiang P Int J Cardiol Cardiovasc Risk Prev. 2023; 19:200225.

PMID: 38077939 PMC: 10698245. DOI: 10.1016/j.ijcrp.2023.200225.


Effect of ivabradine on ventricular arrhythmias in heart failure patients with reduced ejection fraction.

Pay L, Yumurtas A, Tezen O, Cetin T, Keskin K, Eren S Rev Assoc Med Bras (1992). 2023; 69(12):e20230703.

PMID: 37971125 PMC: 10645178. DOI: 10.1590/1806-9282.20230703.


Cost-effectiveness analysis of cardiac implantable electronic devices with reactive atrial-based antitachycardia pacing.

Noda T, Ueda N, Tanaka Y, Ishiguro Y, Matsumoto T, Uenishi T Europace. 2023; 25(3):1087-1099.

PMID: 36691793 PMC: 10062312. DOI: 10.1093/europace/euad003.